期刊
NEUROGENETICS
卷 23, 期 2, 页码 115-127出版社
SPRINGER
DOI: 10.1007/s10048-022-00684-7
关键词
PEX16; Peroxisome biogenesis disorder; Zellweger spectrum disorder; Leukodystrophy; Dystonia; Dopa-responsive dystonia
资金
- Medical Class of 1961 Research Bursary
- Harold and Rhea Pugash Research Bursary
- Canadian Institutes of Health Research (CIHR) [144213]
- Fonds de Recherche du Quebec -Sante (2012-2016, Research Scholar Junior 1 award)
- Canadian Institutes of Health Research (2017-2022, the New Investigator Salary Award)
- Canadian Institutes of Health Research (CIHR)
- Travere Therapeutics, Inc.
This study reviewed the medical records and brain MRIs of 7 patients with PEX16 phenotype, revealing that these patients exhibited some atypical features such as spasticity, cerebellar dysfunction, and prolonged survival. The study also identified novel clinical, neuroradiological, and molecular features of PEX16 defects and proposed a potential treatment for dystonia.
Peroxisome biogenesis disorders-Zellweger spectrum disorders (PBD-ZSD)-are primarily autosomal recessive disorders caused by mutations in any of 13 PEX genes involved in peroxisome assembly. Compared to other PEX-related disorders, some PEX16 defects are associated with an atypical phenotype consisting of spasticity, cerebellar dysfunction, preserved cognition, and prolonged survival. In this case series, medical records and brain MRIs from 7 patients with this PEX16 presentation were reviewed to further characterize this phenotype. Classic PBD features such as sensory deficits and amelogenesis imperfecta were absent in all 7 patients, while all patients had hypertonia. Five patients were noted to have dystonia and received a treatment trial of levodopa/carbidopa. Four treated patients had partial but significant improvements in their dystonia and tremors, and 1 patient had only minimal response. Brain MRI studies commonly showed T2/FLAIR hyperintensities in the brainstem, superior and middle cerebellar peduncles, corticospinal tracts, and splenium of the corpus callosum. Genetic analysis revealed novel biallelic variants in 3 probands (c.683C > T/372delG; c.692A > G homozygous; c.865C > G/451C > T) and 1 novel variant (c.956_958delCGC) in another proband. We demonstrated residual PEX16 protein amounts by immunoblotting in fibroblasts available from 5 patients with this atypical PEX16 disease (3 from this series, 2 previously reported), in contrast to the absence of PEX16 protein in fibroblasts from a patient with the severe ZSD presentation. This study further characterizes the phenotype of PEX16 defects by highlighting novel and distinctive clinical, neuroradiological, and molecular features of the disease and proposes a potential treatment for the dystonia. ClinicalTrials.gov Identifier: NCT01668186. Date of registration: January 2012.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据